Publication AWA
At the Public Information Bulletin of the Agency for Health Technology Assessment and Tarification (AWA) has published reviews analyses for the evaluation of reimbursement applications:
- Enhertu (trastuzumab deruxtecan) in the treatment of patients with cancer of the esophagus, gastroesophageal junction, and stomach
- Piasky (crovalimab) w leczeniu chorych z nocną napadową hemoglobinurią (PNH)
We encourage you to read the full documents and submit comments within the prescribed period of 7 days from the date of publication.
